NASDAQ:CMPS COMPASS Pathways (CMPS) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free CMPS Stock Alerts $7.98 -0.12 (-1.48%) (As of 09:34 AM ET) Add Compare Share Share Today's Range$7.90▼$8.1050-Day Range$8.10▼$12.3752-Week Range$5.01▼$12.75Volume25,854 shsAverage Volume675,678 shsMarket Capitalization$494.28 millionP/E RatioN/ADividend YieldN/APrice Target$47.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get COMPASS Pathways alerts: Email Address COMPASS Pathways MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside467.7% Upside$47.40 Price TargetShort InterestBearish5.05% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 8 Articles This WeekInsider TradingSelling Shares$1.34 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.40) to ($2.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.53 out of 5 starsMedical Sector663rd out of 907 stocksPharmaceutical Preparations Industry299th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingCOMPASS Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCOMPASS Pathways has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.05% of the outstanding shares of COMPASS Pathways have been sold short.Short Interest Ratio / Days to CoverCOMPASS Pathways has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in COMPASS Pathways has recently decreased by 0.63%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCOMPASS Pathways does not currently pay a dividend.Dividend GrowthCOMPASS Pathways does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMPS. Previous Next 2.4 News and Social Media Coverage News SentimentCOMPASS Pathways has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for COMPASS Pathways this week, compared to 2 articles on an average week.Search InterestOnly 16 people have searched for CMPS on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.MarketBeat Follows24 people have added COMPASS Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, COMPASS Pathways insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,338,911.00 in company stock.Percentage Held by InsidersOnly 4.25% of the stock of COMPASS Pathways is held by insiders.Percentage Held by Institutions46.19% of the stock of COMPASS Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for COMPASS Pathways are expected to decrease in the coming year, from ($2.40) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of COMPASS Pathways is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of COMPASS Pathways is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCOMPASS Pathways has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The TradingPubAt first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”But if you want the stock with “Hotspot Dates” hitting NEXT WEEK… About COMPASS Pathways Stock (NASDAQ:CMPS)COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Read More CMPS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMPS Stock News HeadlinesApril 19, 2024 | insidertrades.comCOMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder George Jay Goldsmith Sells 23,881 SharesApril 3, 2024 | insidertrades.comInsider Selling: COMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder Sells 25,750 Shares of StockApril 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 20, 2024 | benzinga.comCompass Pathways Stock (NASDAQ:CMPS), Analyst Ratings, Price Targets, PredictionsApril 20, 2024 | americanbankingnews.comGeorge Jay Goldsmith Sells 23,881 Shares of COMPASS Pathways plc (NASDAQ:CMPS) StockApril 20, 2024 | americanbankingnews.comCantor Fitzgerald Reiterates Overweight Rating for COMPASS Pathways (NASDAQ:CMPS)April 4, 2024 | investing.comCompass Pathways insider sells over $460k in sharesApril 1, 2024 | globenewswire.comCompass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare ConferenceApril 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 1, 2024 | markets.businessinsider.comBuy Rating on COMPASS Pathways: COMP360’s Market Potential and Promising TRD TherapyMarch 31, 2024 | finance.yahoo.com20 Most Depressed Countries in AsiaMarch 30, 2024 | uk.investing.comCompass Pathways co-founders step down from boardMarch 28, 2024 | globenewswire.comCompass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of DirectorsMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for COMPASS Pathways Amid Promising Neuropsychiatric Treatment AdvancesMarch 16, 2024 | investing.comCompass Pathways director sells over $700k in company sharesMarch 5, 2024 | fool.com3 Biopharma Stocks You Don't Want to Miss in the New Bull MarketMarch 1, 2024 | finance.yahoo.comCOMPASS Pathways plc (NASDAQ:CMPS) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | marketwatch.comCompass Pathways Shares Tumble 18% After Warning of Trial DelayFebruary 29, 2024 | finance.yahoo.comCompass Pathways PLC Reports Increased Annual Net Loss Amid Clinical AdvancementsFebruary 29, 2024 | globenewswire.comCompass Pathways Announces Fourth Quarter 2023 Financial Results and Business HighlightsFebruary 27, 2024 | investorplace.comPenny Power Players: 3 Stocks to Watch in the Microcap ArenaFebruary 26, 2024 | globenewswire.comCompass Pathways to participate in upcoming TD Cowen investor conferenceFebruary 22, 2024 | finance.yahoo.comCompass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024February 22, 2024 | globenewswire.comCompass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024February 21, 2024 | investorplace.comMental Health Mavericks: 3 Stocks Changing the GameFebruary 19, 2024 | fool.comWall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.February 19, 2024 | fool.comWall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.See More Headlines Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMPS CUSIPN/A CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees186Year Founded2016Price Target and Rating Average Stock Price Target$47.40 High Stock Price Target$120.00 Low Stock Price Target$16.00 Potential Upside/Downside+485.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.72% Return on Assets-49.46% Debt Debt-to-Equity Ratio0.14 Current Ratio13.33 Quick Ratio13.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.65 per share Price / Book2.22Miscellaneous Outstanding Shares61,940,000Free Float59,310,000Market Cap$501.71 million OptionableOptionable Beta2.48 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Kabir Nath M.A. (Age 60)M.B.A., CEO & Director Comp: $1.31MMr. Matthew Allen Owens (Age 47)General Counsel & Chief Legal Officer Comp: $684.51kDr. Guy Goodwin (Age 76)Chief Medical Officer Comp: $567kMs. Teri Loxam M.B.A. (Age 51)CFO, Principal Financial Officer & Principal Accounting Officer Dr. Greg Ryslik Ph.D.Chief Technology OfficerMr. Stephen D. SchultzSenior Vice President of Investor RelationsMr. Christopher WilliamsChief Communications OfficerMs. Anne BenedictChief People OfficerMr. Lars Christian Wilde (Age 39)Senior Advisor Mr. Trevor MillChief Development OfficerMore ExecutivesKey CompetitorsAnaptysBioNASDAQ:ANABStoke TherapeuticsNASDAQ:STOKArriVent BioPharmaNASDAQ:AVBPArbutus BiopharmaNASDAQ:ABUSAstria TherapeuticsNASDAQ:ATXSView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 37,758 shares on 4/19/2024Ownership: 0.528%George Jay GoldsmithSold 23,881 sharesTotal: $203,704.93 ($8.53/share)George Jay GoldsmithSold 25,750 sharesTotal: $230,720.00 ($8.96/share)Ekaterina MalievskaiaSold 25,750 sharesTotal: $222,737.50 ($8.65/share)George Jay GoldsmithSold 15,740 sharesTotal: $166,529.20 ($10.58/share)View All Insider TransactionsView All Institutional Transactions CMPS Stock Analysis - Frequently Asked Questions Should I buy or sell COMPASS Pathways stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMPS shares. View CMPS analyst ratings or view top-rated stocks. What is COMPASS Pathways' stock price target for 2024? 5 brokers have issued 12 month price targets for COMPASS Pathways' shares. Their CMPS share price targets range from $16.00 to $120.00. On average, they expect the company's stock price to reach $47.40 in the next year. This suggests a possible upside of 467.7% from the stock's current price. View analysts price targets for CMPS or view top-rated stocks among Wall Street analysts. How have CMPS shares performed in 2024? COMPASS Pathways' stock was trading at $8.75 on January 1st, 2024. Since then, CMPS stock has decreased by 4.6% and is now trading at $8.35. View the best growth stocks for 2024 here. When is COMPASS Pathways' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CMPS earnings forecast. How were COMPASS Pathways' earnings last quarter? COMPASS Pathways plc (NASDAQ:CMPS) released its earnings results on Thursday, February, 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.16. What ETFs hold COMPASS Pathways' stock? ETFs with the largest weight of COMPASS Pathways (NASDAQ:CMPS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Subversive Mental Health ETF (SANE), ARK Genomic Revolution ETF (ARKG) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Grizzle Growth ETF (DARP). What other stocks do shareholders of COMPASS Pathways own? Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD), Plug Power (PLUG), Block (SQ), Workhorse Group (WKHS) and When did COMPASS Pathways IPO? COMPASS Pathways (CMPS) raised $100 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are COMPASS Pathways' major shareholders? COMPASS Pathways' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.53%). Insiders that own company stock include David Y Norton, Ekaterina Malievskaia and George Jay Goldsmith. View institutional ownership trends. How do I buy shares of COMPASS Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMPS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceNew Trump BombshellThe Freeport SocietyGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
